These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26854086)

  • 1. BAP1 is overexpressed in black compared with white patients with Mx-M1 clear cell renal cell carcinoma: A report from the cancer genome atlas.
    Paulucci DJ; Sfakianos JP; Yadav SS; Badani KK
    Urol Oncol; 2016 Jun; 34(6):259.e9-259.e14. PubMed ID: 26854086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
    Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
    Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma.
    Kapur P; Christie A; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Xie XJ; Lotan Y; Margulis V; Brugarolas J
    J Urol; 2014 Mar; 191(3):603-10. PubMed ID: 24076305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma.
    Paulucci DJ; Sfakianos JP; Skanderup AJ; Kan K; Tsao CK; Galsky MD; Hakimi AA; Badani KK
    Oncotarget; 2017 Jan; 8(3):5196-5205. PubMed ID: 28029648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
    Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
    Farley MN; Schmidt LS; Mester JL; Pena-Llopis S; Pavia-Jimenez A; Christie A; Vocke CD; Ricketts CJ; Peterson J; Middelton L; Kinch L; Grishin N; Merino MJ; Metwalli AR; Xing C; Xie XJ; Dahia PLM; Eng C; Linehan WM; Brugarolas J
    Mol Cancer Res; 2013 Sep; 11(9):1061-1071. PubMed ID: 23709298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
    da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
    Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
    Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
    Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
    Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
    J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
    Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma.
    Minardi D; Lucarini G; Milanese G; Di Primio R; Montironi R; Muzzonigro G
    Urol Oncol; 2016 Aug; 34(8):338.e11-8. PubMed ID: 27085487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma.
    da Costa WH; da Cunha IW; Fares AF; Bezerra SM; Shultz L; Clavijo DA; da Silva DV; Netto GJ; Guimaraes GC; Cassio Zequi S
    Urol Oncol; 2018 May; 36(5):243.e1-243.e8. PubMed ID: 29426696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
    Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
    Oka S; Inoshita N; Miura Y; Oki R; Miyama Y; Nagamoto S; Ogawa K; Sakaguchi K; Kondoh C; Kurosawa K; Urakami S; Takano T; Okaneya T
    Urol Oncol; 2018 Aug; 36(8):365.e9-365.e14. PubMed ID: 29853346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.